Clinical trial: extended treatment duration of peginterferon‐alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1‐infected late responders

Summary Background The benefits of prolonging peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1‐infected patients remain to be understood. Aim To investigate whether extended treatment longer than 72 week...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2009-08, Vol.30 (4), p.343-351
Hauptverfasser:	NAGAKI, M., SHIMIZU, M., SUGIHARA, J. I., TOMITA, E., SANO, C., NAIKI, T., KIMURA, K., AMANO, K., SAKAI, T., NINOMIYA, M., KOJIMA, T., KATSUMURA, N., FUJIMOTO, M., MORIWAKI, H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analysis of Variance Antiviral Agents - administration & dosage Biological and medical sciences Digestive system Drug Therapy, Combination Female Gastroenterology. Liver. Pancreas. Abdomen Genotype Hepacivirus - genetics Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Hepatitis C, Chronic - virology Human viral diseases Humans Infectious diseases Interferon-alpha - administration & dosage Male Medical sciences Middle Aged Pharmacology. Drug treatments Polyethylene Glycols - administration & dosage Recombinant Proteins Ribavirin - administration & dosage Time Factors Treatment Outcome Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!